The purpose of this study is to investigate the efficacy and safety of different retatrutide dose escalation schemes in participants without type 2 diabetes who have obesity or overweight. Participation in the study will last about 113 weeks.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
600
Administered SC
Percent Change from Baseline in Body Weight
Time frame: Baseline, Week 104
Change from Baseline in Waist Circumference
Time frame: Baseline, Week 104
Percent Change from Baseline in Triglycerides
Time frame: Baseline, Week 104
Change from Baseline in Systolic Blood Pressure
Time frame: Baseline, Week 104
Percent Change from Baseline in High Sensitivity C-Reactive Protein
Time frame: Baseline, Week 104
Change from Baseline in Impact of Weight on Quality of Life-Lite-Clinical Trials (IWQOL-Lite-CT) Total Score
Time frame: Baseline, Week 104
Overall Treatment Satisfaction with Medication for Obesity (TS-MO) Scores
Time frame: Week 104
Pharmacokinetics (PK): Steady state Average Trough PK Concentration
Time frame: Baseline through Week 104
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Arizona Research Center
Phoenix, Arizona, United States
Care Access - Huntington Beach
Huntington Beach, California, United States
Los Angeles Institute for Metabolic Research
Los Angeles, California, United States
New Horizon Research Center
Miami, Florida, United States
Encore Medical Research - Weston
Weston, Florida, United States
Pacific Diabetes & Endocrine Center
Honolulu, Hawaii, United States
Monroe Biomedical Research - Louisville
Louisville, Kentucky, United States
Brigham and Women's Hospital Diabetes Program
Boston, Massachusetts, United States
Great Lakes Research Group, Inc.
Bay City, Michigan, United States
NYC Research INC
Long Island City, New York, United States
...and 25 more locations